PFE
Pfizer Inc. (PFE) Stock Analysis
NYQ
$30.67
▲ +0.49%
Yahoo Finance chart (legacy) quote · as of Nov 2, 2026, 9:30 AM ET
$30.45
Open
$31.04
High
$30.20
Low
$30.52
Prev close
—
Market cap
Analyze PFE in depth →
Free to try, no account needed. Create a free account for 10 analyses a day, financial statements and watchlists.
Pfizer Inc. by the reported numbers
On the most recently reported figures, Pfizer Inc. (PFE) shows revenue down 1.6% and earnings per share down 3.5% year over year.
The business runs a net margin of 12.4%, a free cash flow margin of 14.5% and a 9.1% return on equity.
The ImpliedLens normalized earnings-value model places the shares 74.1% below the current price under its disclosed assumptions, which you can change. At today's price the market is implying 20.1% more growth than the reported figures support.
Valuation
| Forward P/E | 40.4× | Price / trailing four-quarter actual EPS · Jun 28, 2026 |
|---|---|---|
| Model upside | −74.1% | ImpliedLens normalized earnings-value model · Aug 4, 2026 |
| Conservative case | −84.1% | ImpliedLens conservative earnings-value model · Aug 4, 2026 |
| Implied growth gap | +20.1% | ImpliedLens price-expectations model · Aug 4, 2026 |
Growth
| Revenue growth | −1.6% | SEC filing · Aug 4, 2026 |
|---|---|---|
| EPS growth | −3.5% | SEC filing · Aug 4, 2026 |
| Share count change | +0.3% | SEC filing · Aug 4, 2026 |
Profitability and returns
| Net margin | 12.4% | Derived from SEC filing · Aug 4, 2026 |
|---|---|---|
| Free cash flow margin | 14.5% | SEC filing · Aug 4, 2026 |
| Return on equity | 9.1% | Derived from SEC filing · Aug 4, 2026 |
Balance sheet
| Equity / assets | 42.5% | Derived from SEC filing · Aug 4, 2026 |
|---|
Every figure above carries the source it came from and the date it was reported. Company filings as of Aug 4, 2026. Figures are reported and derived data, not advice, and the valuation model is one set of assumptions you can change.
Everything in one place
What you get with ImpliedLens.
Financial statements
Income, balance sheet, cash flow from SEC filings with 30+ calculated ratios.
DCF valuation
Customizable discounted cash flow model with live inputs.
Analyst targets
Price targets, recommendation breakdowns, earnings surprises.
Institutional context
Ownership data and aggregated FINRA OTC activity.
SEC filings
Direct links to 10-K, 10-Q, 8-K, and proxy statements.
Projection models
Bull/base/bear scenario modeling with editable assumptions.
Questions to answer before investing in PFE
01What assumptions does the current PFE price require to deliver an attractive return?
02Can Pfizer Inc. hold a 12.4% net margin with revenue growing −1.6% a year?
03What growth does a 40.4× forward multiple on PFE already assume?
04Which of the model's assumptions is doing the work behind its 74.1% gap to the current PFE price?
05Which risks would invalidate the investment thesis for PFE?
06How does PFE's valuation compare with its growth, quality, and closest alternatives?